MYCN and neuroblastoma: Moreover, studies have revealed significantly poorer outcomes in a subgroup of patients with stage 4S neuroblastoma characterized by MYCN amplification, chromosomal aberrations (1p loss of heterozygosity, 11q aberration, 17q gain), diploidy, and age of < 2 months at diagnosis [1, 8–12].